Table 2.
Clinical survey responses regarding cribriform and intraductal carcinoma in needle biopsy scenarios
| Question | All Responses (N=834)* | Urology (N=580) | Radiation Oncology (N=186) |
|---|---|---|---|
| Q19: For cases with GS 7 (Grade groups 2–3), would knowing if the pattern 4 component was cribriform vs. not cribriform affect patient counseling or management? | YES: 44% (N=241) NO: 56% (N=311) [Responses: 552] |
YES: 50% (N=196) NO: 50% (N=196) [Responses: 392] |
YES: 24% (N=29) NO: 76% (N=92) [Responses: 121] |
| Q21: If you would consider active surveillance in men with GS 3+4=7 (Grade group 2) who have over 10-year life expectancy, does whether the pattern 4 component is cribriform vs. not cribriform impact the decision? | YES: 63% (N=197) NO: 37% (N=114) [Responses: 311] |
YES: 71% (N=159) NO: 29% (N=65) [Responses: 224] |
YES: 34% (N=20) NO: 66% (N=39) [Responses: 59] |
| Q22: Would you recommend active surveillance for a man with cancer who is otherwise a candidate if their NB also shows intraductal carcinoma? | YES: 29% (N=153) NO: 71% (N=381) [Responses: 534] |
YES: 24% (N=89) NO: 76% (N=289) [Responses: 378] |
YES: 41% (N=49) NO: 59% (N=70) [Responses: 119] |
| Q24: If a biopsy shows GS 6 and intraductal carcinoma, do you routinely perform repeat biopsy to look for higher grade cancer? | YES: 35% (N=188) NO: 65% (N=344) [Responses: 532] |
YES: 33% (N=125) NO: 67% (N=253) [Responses: 378] |
YES: 38% (N=45) NO: 62% (N=73) [Responses: 118] |
| Q25: If a biopsy report indicates that there is intraductal carcinoma in addition to invasive cancer with GS 7–10 (Grade groups 2–5), would it affect therapy selection? | YES: 31% (N=165) NO: 69% (N=369) [Responses: 534] |
YES: 29% (N=108) NO: 71% (N=270) [Responses: 378] |
YES: 34% (N=41) NO: 66% (N=78) [Responses: 119] |
*
Also includes responses from Medical Oncologists (N=46) and ‘Other’ (N=22)
GS: Gleason score; NB: needle biopsy